Skip to main content

 

DMD Advocates has advised HBM Healthcare Investments and other associated investors in leading OneSource Specialty Pharma’s $100 million fundraising through a pre-listing round, with DSK Legal representing OneSource on the deal. 

OneSource Specialty Pharma (formerly known as Stelis Biopharma), a contract development and manufacturing organisation (CDMO) platform, is an associate of Strides Pharma and its shares are to be listed shortly. 

The capital raised will support OneSource's growth, advance its research and development efforts, and expand its product offerings, which will strengthen the company's market position ahead of its initial public offering (IPO), according to a company statement.

The healthcare sector remains busy with dealmaking and private equity in the country, with $3.8 billion in deal value recorded in 2024. This figure includes Mankind Pharma's $1.6 billion acquisition of Bharat Serums and Vaccines.

The DMD team involved in the deal was led by partners Ayesha Rai and Vihang Virkar, with contributions from principal associate Pooja Shah and associate Vanshikha Choraria.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Luthra, AZB, CAM act on JSW Steel’s $482 mln acquisition of ThyssenKrupp Electrical

by Nimitt Dixit |

Luthra and Luthra Law Offices India, along with AZB & Partners, advised a consortium of JSW Steel and JFE Steel Corporation and their JV on their $482.1 million proposed acquisition of ThyssenKrupp Electrical Steel India, which was represented by Cyril Amarchand Mangaldas.

Deals

TT&A, Khaitan, AZB guide Macquarie-backed Blueleaf’s $400 mln India solar bet

by Nimitt Dixit |

Talwar Thakore & Associates and AZB & Partners have advised Singapore-based Blueleaf Energy (BLE) on its $400 million investment in 1 gigawatt of solar projects in the northwestern Indian state of Rajasthan owned by Jakson Green, which was represented by Khaitan & Co.

Deals

SAM, CAM, White & Case act on $146 mln Carraro IPO

by Nimitt Dixit |

Shardul Amarchand Mangaldas & Co has advised Carraro India and its Italian parent Carraro International on its initial public offering worth $146 million.